Donald A. Bergstrom, President of R&D at Relay Therapeutics, Inc., filed a Form 4 on November 20, 2026, disclosing the sale of 10,269 shares of common stock on November 18, 2026, under a Rule 10b5-1 trading plan.

Key Highlights

  • Shares sold: 10,269 shares of Relay Therapeutics common stock were disposed of on November 18, 2026.
  • Weighted average price: The transaction was reported at a weighted average sale price of $16.51 per share, with individual trades ranging from $16.30 to $16.99.
  • 10b5-1 plan: The sale was made pursuant to a Rule 10b5-1 trading plan adopted by Bergstrom on October 30, 2025.
  • Remaining ownership: Following the transaction, Bergstrom beneficially owned 386,609 shares directly, including 5,013 shares underlying restricted stock units.
  • Reporting person role: Bergstrom is identified as President, R&D at Relay Therapeutics, Inc. (NASDAQ:RLAY).

Bergstrom's November 2026 Share Sale Under Pre-Established Trading Plan

According to the filing, Donald A. Bergstrom, who serves as President, R&D at Relay Therapeutics, Inc., disposed of 10,269 shares of the company's common stock on November 18, 2026. The transaction was coded "S" (sale) in Table I of the Form 4, indicating a sale of non-derivative securities. The filing notes that the sale was executed in multiple trades at prices ranging from $16.30 to $16.99 per share, with $16.51 representing the weighted average sale price. Bergstrom's filing states that full information on the number of shares sold at each individual price within the range will be provided upon request to the SEC staff, the issuer, or a security holder.

The filing discloses that the reported transaction was carried out pursuant to a Rule 10b5-1 trading plan that Bergstrom adopted on October 30, 2025. The Form 4 box indicating a Rule 10b5-1(c) plan was checked, confirming the sale was made under a pre-established written plan. Following the reported transaction, Bergstrom directly beneficially owned 386,609 shares of common stock, a figure that the filing states includes 5,013 shares underlying restricted stock units. No derivative securities transactions were reported in Table II of the filing.

The Form 4 was signed by Soo-Yeun Lim as Attorney-in-Fact and filed on November 20, 2026, covering a transaction with a date of earliest transaction of November 18, 2026. The filing was submitted on behalf of one reporting person and indicates direct ownership of all reported securities.

What Was Disclosed

Relay Therapeutics President of R&D Donald A. Bergstrom filed a Form 4 disclosing a sale of 10,269 common shares on November 18, 2026, at a weighted average price of $16.51, executed under a Rule 10b5-1 plan adopted October 30, 2025, leaving him with 386,609 shares beneficially owned.